USANA Health Sciences, Inc. (NYSE:USNA) Major Shareholder Myron W. Wentz Sells 2,202 Shares

USANA Health Sciences, Inc. (NYSE:USNA) major shareholder Myron W. Wentz sold 2,202 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $47.79, for a total value of $105,233.58. Following the completion of the sale, the insider now directly owns 7,877,841 shares of the company’s stock, valued at approximately $376,482,021.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

USANA Health Sciences Price Performance

USNA opened at $44.96 on Monday. USANA Health Sciences, Inc. has a 1-year low of $41.45 and a 1-year high of $69.60. The stock has a market cap of $856.49 million, a P/E ratio of 14.01, a P/E/G ratio of 1.35 and a beta of 0.93. The stock’s 50 day simple moving average is $46.10 and its 200 day simple moving average is $48.23.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, April 30th. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.17. The company had revenue of $227.80 million for the quarter, compared to analyst estimates of $223.27 million. USANA Health Sciences had a return on equity of 12.80% and a net margin of 6.88%. Research analysts expect that USANA Health Sciences, Inc. will post 2.78 EPS for the current fiscal year.

Hedge Funds Weigh In On USANA Health Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pacer Advisors Inc. grew its position in shares of USANA Health Sciences by 75.7% in the fourth quarter. Pacer Advisors Inc. now owns 337,371 shares of the company’s stock valued at $18,083,000 after purchasing an additional 145,373 shares during the last quarter. Vanguard Group Inc. lifted its stake in USANA Health Sciences by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,567,182 shares of the company’s stock valued at $91,853,000 after buying an additional 38,533 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in USANA Health Sciences by 58.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 82,199 shares of the company’s stock valued at $3,987,000 after buying an additional 30,485 shares during the last quarter. Pzena Investment Management LLC increased its position in USANA Health Sciences by 3.1% during the first quarter. Pzena Investment Management LLC now owns 785,344 shares of the company’s stock worth $38,089,000 after buying an additional 23,729 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of USANA Health Sciences by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 677,664 shares of the company’s stock worth $36,323,000 after acquiring an additional 21,524 shares during the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

Analyst Ratings Changes

Separately, DA Davidson reduced their price objective on shares of USANA Health Sciences from $48.00 to $46.00 and set a “neutral” rating for the company in a research note on Tuesday, May 7th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.